123
Participants
Start Date
December 17, 2024
Primary Completion Date
July 17, 2029
Study Completion Date
July 17, 2030
Rapcabtagene autoleucel
Single infusion of rapcabtagene autoleucel
Active Comparator Option
Investigator choice of treatment as per protocol
RECRUITING
Novartis Investigative Site, Taipei
RECRUITING
Novartis Investigative Site, Milan
RECRUITING
Novartis Investigative Site, Hamburg
RECRUITING
Novartis Investigative Site, Brescia
RECRUITING
Novartis Investigative Site, Brest
RECRUITING
Novartis Investigative Site, Pamplona
RECRUITING
Novartis Investigative Site, Rennes
RECRUITING
Novartis Investigative Site, Cologne
RECRUITING
University Of Iowa, Iowa City
RECRUITING
Northwestern University, Chicago
RECRUITING
Novartis Investigative Site, Lyon
RECRUITING
Novartis Investigative Site, Paris
RECRUITING
LDS Hospital, Salt Lake City
RECRUITING
Novartis Investigative Site, Singapore
RECRUITING
Novartis Investigative Site, Singapore
RECRUITING
Novartis Investigative Site, Taichung
RECRUITING
Novartis Investigative Site, Haifa
RECRUITING
Novartis Investigative Site, Ramat Gan
RECRUITING
Novartis Investigative Site, Tel Aviv
RECRUITING
Novartis Investigative Site, Leipzig
RECRUITING
Novartis Investigative Site, Jena
RECRUITING
Novartis Investigative Site, Sapporo
RECRUITING
Novartis Investigative Site, Kanazawa
RECRUITING
Novartis Investigative Site, Sendai
RECRUITING
Novartis Investigative Site, Suita
RECRUITING
Novartis Investigative Site, Izumo
RECRUITING
Novartis Investigative Site, Bunkyo-ku
RECRUITING
Novartis Investigative Site, Kyoto
RECRUITING
Novartis Investigative Site, Singapore
RECRUITING
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY